Testing effectiveness (Phase 2)Looking for participantsNCT07207408
What this trial is testing
Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
Who this might be right for
Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis
Dynavax Technologies Corporation 148